HCV dispute blamed for Murex' loss
This article was originally published in Clinica
Executive Summary
Murex has reported a net loss of $2.1 million in the third quarter ended September 30th, 1995, compared with a net income of $1.5 million in the same period last year. The Canadian company blames the continuing HCV patent dispute with Chiron. Because of the litigation, Murex has moved its HCV production site twice - to Italy and more recently to Morocco. Problems associated with this final move resulted in a $1.1 million loss in HCV sales, says Murex.